NEW YORK (GenomeWeb) – Eisai subsidiary Morphotek today announced a collaboration and licensing agreement with Fujirebio Diagnostics to validate and commercialize the CA125 II assay as a companion diagnostic to identify best responders to Morphotek's investigational ovarian cancer treatment.
To read the full story....
Register for Free....and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.